News tagged with bortezomib
Searching for therapeutic synergy in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with ...
Cancer
May 01, 2013 |
not rated yet |
0
Medication duloxetine helps reduce pain from chemotherapy
Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April ...
Cancer
Apr 02, 2013 |
4 / 5 (1) |
0
New multiple myeloma treatment guidelines personalize therapy for patients
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to ...
Cancer
Apr 01, 2013 |
not rated yet |
0
New compound holds high promise in battling kidney cancer
Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.
Cancer
Feb 19, 2013 |
1 / 5 (1) |
0
Scientists find new molecule to target in pancreatic cancer treatment
Researchers at Mayo Clinic in Florida have identified a new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more than 95 percent of pancreatic cancer cases. This fast-growing, often ...
Cancer
Jan 03, 2013 |
5 / 5 (2) |
0
|
Possible new therapy for the treatment of myeloma
(Medical Xpress)—Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common ...
Cancer
Sep 05, 2012 |
not rated yet |
0
|
Bortezomib beneficial in graft-versus-host disease prophylaxis
(HealthDay) -- Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor (MMUD) reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) may benefit from ...
Cancer
Aug 08, 2012 |
not rated yet |
0
Bortezomib ups response, survival in multiple myeloma
(HealthDay) -- For patients with newly diagnosed multiple myeloma (MM), induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance therapy ...
Cancer
Jul 23, 2012 |
not rated yet |
0
Kyprolis approved for multiple myeloma
(HealthDay) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.
Cancer
Jul 20, 2012 |
not rated yet |
0
Powerful myeloma treatment regimen shows promise for AL amyloidosis
Two studies published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devast ...
Cancer
Feb 13, 2012 |
not rated yet |
0
Cancer drug may also work for scleroderma
A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.
Medications
Sep 22, 2011 |
5 / 5 (1) |
0
|
In the lab and clinic, researchers develop a new therapy for blood cancers
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving ...
Cancer
Jun 02, 2011 |
not rated yet |
0
|
Bortezomib
Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
For more information about Bortezomib, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
